View in EDS HTML Full Text PDF Full Text

352 | 5‐YEAR UPDATE ON FRONTLINE BRENTUXIMAB VEDOTIN WITH AVD FOR STAGE II‐IV HIV‐ASSOCIATED CLASSICAL HODGKIN LYMPHOMA (AMC‐085).

Saved in:
Bibliographic Details
Title: 352 | 5‐YEAR UPDATE ON FRONTLINE BRENTUXIMAB VEDOTIN WITH AVD FOR STAGE II‐IV HIV‐ASSOCIATED CLASSICAL HODGKIN LYMPHOMA (AMC‐085).
Authors: Rubinstein, P. G., Kwon, D., Rudek, M. A., Chadburn, A., Ratner, L., Henry, D. H., Cesarman, E., Ramos, J. C., Sharon, E., Reid, E. G., Ambinder, R. F., Mitsuyasu, R., Mounier, N., Besson, C., Noy, A.
Source: Hematological oncology 2025 Supplement; Vol. 43.
Journal Info: Publisher: Wiley-Blackwell ISSN: 0278-0232
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1099-1069
DOI:10.1002/hon.70094_352